Drug Profile
Research programme: BACE2 protein inhibitors - Jortan Pharmaceuticals
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Jortan Pharmaceuticals
- Class Small molecules
- Mechanism of Action BACE2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 23 Aug 2016 Research programme: BACE2 protein inhibitors - Jortan Pharmaceuticals is available for licensing as of 23 Aug 2016. http://jortanpharma.com/about/
- 23 Aug 2016 Jortan Pharmaceuticals has patent protection for BACE2 inhibitors (Jortan Pharmaceuticals website) before August 2016